

7 August 2026

Treatment of Cancers (to include ovarian, fallopian tube, primary peritoneal and prostate cancers)

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2026 and the end of June 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
1.1 Niraparib (Zejula)	50
1.2 Rucaparib (Rubraca)	6
1.3 Olaparib (Lynparza)	28
1.4 Cemiplimab (Libtayo)	15
1.5 Mirvetuximab soravtansine (Elahere)	<5

Q2. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Olaparib for all ovarian, fallopian tube or primary peritoneal cancers	23
2.2 Olaparib + bevacizumab	0
2.3 Olaparib monotherapy	23
2.4 Bevacizumab or all ovarian, fallopian tube or primary peritoneal cancers	17
2.5 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	0
2.6 Bevacizumab monotherapy	0

7 August 2026

Q3. How many patients were treated with rucaparib (Rubraca) for the following indications in the 3 months between 1st April 2026 to the end of June 2026 or latest 3-months for which data are available?

Rucaparib Line of Therapy (indication) and NICE TA code	Number patients treated
3.1 1L advanced ovarian cancer in response to 1L platinum chemotherapy (TA1055)	
3.2 Relapsed platinum-sensitive ovarian cancer (TA1007)	

Belfast Trust does not hold the information requested. Therefore, Section 1(1)(a) of the Freedom of Information Act 2000 applies, as the requested information relating to the number of patients treated with rucaparib (Rubraca) for the indications listed is not held by the Trust.

Q4. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines in the 3 months between 1st April 2025 to the end of June 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
4.1 Dostarlimab (Jemperli)	10
4.2 Pembrolizumab (Keytruda)	<5
4.3 Lenvatinib (Lenvima)	0
4.4 Durvalumab (Imfinzi)	0

Q5. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
5.1 Dostarlimab monotherapy	<5
5.2 Dostarlimab in combination with Chemotherapy	7
5.3 Pembrolizumab monotherapy	<5
5.4 Pembrolizumab + Lenvatinib in combination	0
5.5 Pembrolizumab in combination with Chemotherapy	<5
5.6 Durvalumab with Carboplatin and Paclitaxel	0
5.7 Durvalumab monotherapy	0
5.8 Durvalumab + Olaparib combination	0

7 August 2026

Q6. How many patients with Endometrial Cancer (C54.1) received the following treatments by subtype deficient mismatch repair (dMMR) and proficient mismatch repair (pMMR) within the last 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available?

Name of combination or monotherapy	dMMR Patients	pMMR Patients
6.1 Dostarlimab + Carboplatin + Paclitaxel	<5	<5
6.2 Pembrolizumab + Carboplatin + Paclitaxel	0	<5
6.3 Pembrolizumab + Lenvatinib	0	0
6.4 Dostarlimab as monotherapy at cycle 1	0	0
6.5 Dostarlimab as monotherapy maintenance (cycle 7+)	<5	<5
6.6 Pembrolizumab as monotherapy at cycle 1 (1 - unknown MMR subtype)	-	-
6.7 Pembrolizumab as monotherapy maintenance (cycle 7+)	0	0

Q7. How many patients were treated with cemiplimab (Libtayo) for the following types of cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Tumour type	Number patients treated
7.1 Cutaneous Squamous Cell Carcinoma	15
7.2 Basal Cell Carcinoma	0
7.3 Non-small Cell Lung Cancer	0
7.4 Cervical Cancer	0

Q8. How many patients treated with cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma were treated with the following treatment intent in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Treatment intent	Number patients treated
8.1 Curative	0
8.2 Palliative	15

7 August 2026

Q9. How many patients received cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma as adjuvant treatment in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Treatment intent	Number patients treated
9.1 Adjuvant	0

Some figures have been withheld and replaced with less than five (<5). This is because disclosure of small numbers has the potential to identify individuals. The information is therefore exempt under Section 40(2) of the Freedom of Information Act 2000 - Personal Information relating to a third party. Its release would contravene the data protection principles set out in the UK GDPR.